Recombinant human erythropoietin and platinum-based chemotherapy in advanced ovarian cancer.

Abstract

Epoetin alfa appears to be effective and well tolerated in preventing hemoglobin decline in patients undergoing aggressive cyclic platinum-based chemotherapy for advanced ovarian carcinoma.